Department of Plastic Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Surgery, University of Chicago, Chicago, Illinois, USA.
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001583.
Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarkers. The success of biomarker development is dependent on accurate and timely collection of biospecimens and high-quality processing, storage and shipping. Tumors are also increasingly used as source material for the generation of therapeutic T cells. There have been few guidelines or consensus statements on how to optimally collect and manage biospecimens and source material being used for immunotherapy and related research. The Society for Immunotherapy of Cancer Surgery Committee has brought together surgical experts from multiple subspecialty disciplines to identify best practices and to provide consensus on how best to access and manage specific tissues for immuno-oncology treatments and clinical investigation. In addition, the committee recommends early integration of surgeons and other interventional physicians with expertise in biospecimen collection, especially in clinical trials, to optimize the quality of tissue and the validity of correlative clinical studies in cancer immunotherapy.
免疫疗法现已成为癌症治疗的基石，人们高度关注预后和预测生物标志物的鉴定。生物标志物的开发能否成功取决于生物样本的准确、及时采集以及高质量的处理、储存和运输。肿瘤也越来越多地被用作生成治疗性 T 细胞的材料。目前，关于如何优化免疫疗法和相关研究中生物样本和源材料的采集和管理，几乎没有指南或共识声明。癌症免疫治疗与研究协会外科委员会(Society for Immunotherapy of Cancer Surgery Committee)召集了来自多个亚专科的外科专家，以确定最佳实践，并就如何最好地获取和管理用于免疫肿瘤学治疗和临床研究的特定组织达成共识。此外，该委员会建议外科医生和其他介入医学专家尽早介入生物样本采集，特别是在临床试验中，以优化癌症免疫治疗中组织的质量和相关临床研究的有效性。
